Figure 6.

Xcl1(Δ1)-targeting results in protection from lethal PR8 challenge. (A) BALB/c mice were vaccinated as described in Figure 3, and challenged 6 weeks later with 5xLD50 of PR8 virus. Weight loss was monitored as a measure of disease progression. (B) Sera were harvested 6 weeks after vaccination, and transferred to naïve mice. The following day, the recipient mice were challenged with a 2,5xLD50 of PR8. (C) Survival plot of the mice presented in (B). (D) 12 weeks after vaccination, mice received either anti-CD8 and anti-CD4 depleting mAbs, or isotype matched mAbs 3 days before, the day of, and 3 days after challenge with 5xLD50 of PR8. As in (B), weight loss was monitored as a measure of disease progression. (E) Microneutralization was done with different dilutions of sera from vaccinated mice. (F) Serum transfer to naïve mice was done 6 weeks after the first immunization, 3 weeks after the second for boosted mice and mice were challenged with a 5XLD50 dose of PR8. (A) n = 12 for vaccine groups, n = 6 for NaCl group. (B–F) n = 6. (A,B,D–F) Data shown are mean ± SEM. Two-way ANOVA with Tukey's multiple comparisons test, (C) Mantel-Cox. *p < 0.05, **p < 0.01, ***p < 0.001.